日期 | 股東名稱 | 披露原因 | 買入/賣出涉及 的股份數目 |
每股平均價 | 持有權益的 股份數目 |
佔已發行 股本(%) |
03/09/2024 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD3.920(L) | 1,123,456,000(L) | 37.84 |
02/09/2024 | 曲繼廣 | 1113(L) | +2,000,000(L) | HKD3.873(L) | 1,122,056,000(L) | 37.79 |
02/09/2024 | 曲繼廣 | 1101(L) | +400,000(L) | HKD3.811(L) | 1,122,456,000(L) | 37.80 |
02/09/2024 | China Pharmaceutical Company Limited | 1710(L) | +2,000,000(L) | HKD3.873(L) | 837,048,000(L) | 28.19 |
30/08/2024 | China Pharmaceutical Company Limited | 1710(L) | +2,350,000(L) | HKD3.890(L) | 835,048,000(L) | 28.12 |
30/08/2024 | 曲繼廣 | 1113(L) | +2,350,000(L) | HKD3.890(L) | 1,120,056,000(L) | 37.72 |
21/08/2024 | 四川科倫藥業股份有限公司 | 1101(L) | +5,930,000(L) | HKD3.536(L) | 628,776,000(L) | 21.18 |
18/04/2024 | China Pharmaceutical Company Limited | 1710(L) | +1,000,000(L) | HKD4.675(L) | 832,698,000(L) | 28.05 |
18/04/2024 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD4.675(L) | 1,117,706,000(L) | 37.65 |
17/04/2024 | 曲繼廣 | 1113(L) | +800,000(L) | HKD4.763(L) | 1,116,706,000(L) | 37.61 |
17/04/2024 | China Pharmaceutical Company Limited | 1101(L) | +800,000(L) | HKD4.763(L) | 831,698,000(L) | 28.01 |
05/04/2024 | China Pharmaceutical Company Limited | 1710(L) | +524,000(L) | HKD4.815(L) | 830,898,000(L) | 27.98 |
05/04/2024 | 曲繼廣 | 1113(L) | +524,000(L) | HKD4.815(L) | 1,115,906,000(L) | 37.58 |
03/04/2024 | 曲繼廣 | 1101(L) | +1,500,000(L) | HKD5.009(L) | 1,115,382,000(L) | 37.57 |
02/04/2024 | 曲繼廣 | 1113(L) | +2,000,000(L) | HKD5.122(L) | 1,113,882,000(L) | 37.52 |
02/04/2024 | China Pharmaceutical Company Limited | 1710(L) | +2,000,000(L) | HKD5.122(L) | 830,374,000(L) | 27.97 |
28/03/2024 | 曲繼廣 | 1101(L) | +500,000(L) | HKD4.904(L) | 1,111,882,000(L) | 37.45 |
08/03/2024 | UBS Group AG | 1205(L) | -251,000(L) | 296,869,657(L) | 9.99 | |
07/03/2024 | UBS Group AG | 1313(L) | 554,000(L) | 297,084,657(L) | 10.01 | |
06/03/2024 | UBS Group AG | 1104(L) | +255,000(L) | 297,092,657(L) | 10.01 | |
04/03/2024 | UBS Group AG | 1205(L) | -51,335(L) | 296,855,657(L) | 9.99 | |
03/01/2024 | UBS Group AG | 1306(L) | 388,000(L) | 304,670,509(L) | 10.26 | |
14/12/2023 | 曲繼廣 | 1113(L) | +1,500,000(L) | HKD4.929(L) | 1,111,382,000(L) | 37.43 |
14/12/2023 | China Pharmaceutical Company Limited | 1710(L) | +1,500,000(L) | HKD4.929(L) | 828,374,000(L) | 27.90 |
08/12/2023 | 曲繼廣 | 1113(L) | +450,000(L) | HKD4.731(L) | 1,109,882,000(L) | 37.38 |
08/12/2023 | China Pharmaceutical Company Limited | 1710(L) | +450,000(L) | HKD4.731(L) | 826,874,000(L) | 27.85 |
07/12/2023 | 曲繼廣 | 1113(L) | +694,000(L) | HKD4.740(L) | 1,109,432,000(L) | 37.36 |
07/12/2023 | China Pharmaceutical Company Limited | 1710(L) | +694,000(L) | HKD4.740(L) | 826,424,000(L) | 27.83 |
05/12/2023 | 曲繼廣 | 1101(L) | +1,000,000(L) | HKD4.741(L) | 1,108,738,000(L) | 37.34 |
04/12/2023 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD4.796(L) | 1,107,738,000(L) | 37.31 |
04/12/2023 | China Pharmaceutical Company Limited | 1710(L) | +1,000,000(L) | HKD4.796(L) | 825,730,000(L) | 27.81 |
24/11/2023 | 曲繼廣 | 1113(L) | +600,000(L) | HKD4.961(L) | 1,106,738,000(L) | 37.26 |
24/11/2023 | China Pharmaceutical Company Limited | 1710(L) | +600,000(L) | HKD4.961(L) | 824,730,000(L) | 27.76 |
03/11/2023 | China Pharmaceutical Company Limited | 1710(L) | +500,000(L) | HKD4.386(L) | 824,130,000(L) | 27.74 |
03/11/2023 | 曲繼廣 | 1113(L) | +500,000(L) | HKD4.386(L) | 1,106,138,000(L) | 37.24 |
31/10/2023 | China Pharmaceutical Company Limited | 1710(L) | +1,000,000(L) | HKD4.340(L) | 823,630,000(L) | 27.73 |
31/10/2023 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD4.340(L) | 1,105,638,000(L) | 37.23 |
18/10/2023 | UBS Group AG | 1306(L) | 120,000(L) | 306,908,509(L) | 10.33 | |
05/10/2023 | China Pharmaceutical Company Limited | 1710(L) | +500,000(L) | HKD4.375(L) | 822,630,000(L) | 27.69 |
05/10/2023 | 曲繼廣 | 1113(L) | +500,000(L) | HKD4.375(L) | 1,104,638,000(L) | 37.19 |
1 2 3 |
備註: | (L) - 長倉:包括 (1) 持有股份;(2) 透過持有、沽出或發行金融合約,有權或有責任購買相關股份。 |
(S) - 短倉:包括 (1) 借入股份;(2) 透過持有、沽出或發行金融合約,有權或有責任沽出相關股份。 | |
(P) - 可供借出的股份 | |
即時報價更新時間為 18/12/2024 16:17 | |
港股即時基本市場行情由香港交易所提供; 香港交易所指定免費發放即時基本市場行情的網站 | |
新聞
股票
期貨期權N
權證
ETF
A股
外匯黃金
加密貨幣
基金
MPF